Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

6.6K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.6K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

4.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K
Hormonal Regulation01:40

Hormonal Regulation

37.6K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
37.6K
Hormonal Regulation01:33

Hormonal Regulation

30.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
30.4K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic and transcriptional effects of bazedoxifene/conjugated estrogens in a model of obesity-associated breast cancer risk.

JCI insight·2025
Same author

Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.

Clinical breast cancer·2025
Same author

Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.

Contemporary clinical trials·2024
Same author

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.

Breast cancer research : BCR·2024
Same author

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

Menopause (New York, N.Y.)·2024
Same author

Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells.

PloS one·2022

Related Experiment Video

Updated: May 1, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K

An overview of current and emerging SERMs.

Barry S Komm1, Sebastian Mirkin1

  • 1Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA.

The Journal of Steroid Biochemistry and Molecular Biology
|March 27, 2014
PubMed
Summary

Selective estrogen receptor modulators (SERMs) offer tissue-specific effects for conditions like osteoporosis and menopausal symptoms. Newer SERM-estrogen combinations aim to balance benefits while improving endometrial safety.

Keywords:
Bone mineral densityBreast cancerEndometrial cancerMenopauseOsteoporosisSelective estrogen receptor modulators

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

9.7K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K

Related Experiment Videos

Last Updated: May 1, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

9.7K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • Selective estrogen receptor modulators (SERMs) display tissue-specific estrogen receptor (ER) agonist or antagonist activity.
  • SERMs are utilized for breast cancer, osteoporosis, and menopausal symptom management.
  • Endometrial safety profiles differentiate SERMs, with tamoxifen increasing uterine risks while raloxifene and bazedoxifene show neutral effects.

Purpose of the Study:

  • To review the clinical applications and evolving landscape of SERMs.
  • To highlight the importance of endometrial safety in SERM selection.
  • To discuss emerging strategies, such as tissue selective estrogen complexes, for optimizing SERM therapy.

Main Methods:

  • Literature review of SERM mechanisms, clinical applications, and safety data.
  • Comparative analysis of endometrial effects among different SERMs.
  • Exploration of novel therapeutic combinations involving SERMs and estrogens.

Main Results:

  • SERMs provide valuable treatment options, particularly for women intolerant to other therapies or at high fracture risk.
  • Raloxifene and bazedoxifene demonstrate favorable endometrial profiles compared to tamoxifen.
  • Tissue selective estrogen complexes integrate SERM selectivity with estrogenic benefits for vasomotor symptoms, vulvar-vaginal atrophy, and bone mass.

Conclusions:

  • Advances in understanding SERM-ER interactions are driving the development of new, tailored treatments.
  • Optimizing SERM therapy requires consideration of tissue-specific effects and patient needs.
  • Novel approaches like tissue selective estrogen complexes hold promise for comprehensive postmenopausal care.